I had the honor of interviewing Kenneth Harris, Chief Advisor for CuraSense Advisors about cord blood industry growth rates and trends. There are many misleading metrics being released about the cord blood banking industry, so it was an honor to speak with another person who is extremely knowledgeable about the cord blood banking field. In this interview, we explore growth rates for the global cord blood industry, key trends affecting the industry, differences in geographic opportunities and more. Enjoy. [Read more…]
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
Regenerative Applications Of Placental Tissue Allografts With Dr. Bruce Werber
I had the honor of interviewing Dr. Bruce Werber about the regenerative applications of placental tissue allografts. In addition to being a board-certified foot and ankle surgeon for 35 years, Dr. Werber is the COO of BioTech, Products, Services, and Research (BPSR) and the CEO of its subsidiary Anu Life Sciences. [Read more…]
ORIG3N, World’s Largest Blood Cell Repository for iPS Cell Production
ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]
Inside Scoop on Biostage, a World Leader in Bioengineered Organs
Biostage is a clinical-stage company specializing in bioengineered organ implants to treat cancer and other conditions involving the esophagus, bronchus and trachea. In August 2017, Biostage transplanted its esophageal implant product into its first patient worldwide, a 75-year old man with cancer. On the heels of this historic accomplishment, I am pleased to share this interview with Jim McGorry, President and CEO at Biostage, Inc. In this interview, we discuss the company’s vision, its research partnerships, clinical trial strategy, and five-year goals.
Please note that this interview was conducted prior to Biostage’s breach and failure to fund by First Pecos.
Read on to learn more about how Biostage is introducing bioengineered organ implants to the regenerative medicine landscape. [Read more…]
Will Glycostem Release 1st Allogeneic NK Cell Product with Off-the-Shelf Potential?
This interview comes shortly after Novartis became the first company to get a gene therapy approved in the United States, the CAR-T cell therapy, Kymriah®. The historic event demonstrates to investors, the public and funding providers alike that cell therapy is a sector that has emerged, no longer one that is evolving in the future. There are close to 40 companies developing redirected T cells or NK cells for therapeutic use. There are also 800+ cell therapy clinical trials underway around the world, and a considerable amount of research and preclinical work taking place across the cell therapy sector.
In the light of the recent Gilead takeover of Kite Pharma for $11 billion, the cellular immunotherapy sector is in focus among both investors and oncology and non-oncology companies. The search for the “next Kite” has begun!
Glycostem is a 10-year old clinical stage cellular immunotherapy company based in The Netherlands. The uniqueness around Glycostem, beyond that it is a privately funded company with strong phase I safety clinical trial data, is that it may become the first company with an allogeneic off-the- shelf product (oNKord®). This would potentially position NK cell technology to leapfrog CAR-T cell products, due to a safer profile, lower production costs, off-the- shelf status and positive clinical trial data. [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 15
- Next Page »